Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954911 | 0.75 | HTR2A (0.38) | ALDH1A1MAPT | |
| SCHEMBL20230871 | 0.73 | HTR2A (0.37) | KDM4EMAPT | |
| SCHEMBL25118500 | 0.73 | HTR2A (0.37) | MAPT | |
| SCHEMBL22825592 | 0.68 | CYP1A2 (0.50) | — | |
| SCHEMBL20098087 | 0.66 | NPSR1 (0.32) | KDM4EALDH1A1 | |
| SCHEMBL23979051 | 0.65 | KDM4E (0.41) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL20155649 | 0.64 | HTR2A (0.41) | ALDH1A1MAPT | |
| SCHEMBL20156144 | 0.62 | — | — | |
| SCHEMBL14072852 | 0.62 | ALDH1A1 (0.48) | KDM4EMEN1ALDH1A1F2MAPT | |
| SCHEMBL84390 | 0.62 | MAPT (0.60) | KDM4EMEN1ALDH1A1F2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021194959-A1 | TREATMENT OF EYE DISORDERS WITH URIDINE PHOSPHATE DERIVATIVES | GLIAGUARD, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-11072627-B2 | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders | TUFTS UNIVERSITY (US) | 2021-07-27 | — | — | US | disclosed |
| US-20190309009-A1 | URIDINE DIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | TUFTS UNIVERSITY | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190309009-A1 | URIDINE DIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | P2RY6, P2RX6, P2RY1 | TRPM8 588/4885KDM4E 4387/4885MEN1 4598/4885 |
| US-11072627-B2 | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders | P2RY6, P2RX6, P2RY1 | TRPM8 587/4885KDM4E 4335/4885MEN1 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.